About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Grass Observational Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02075138

Grass Observational Study

Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans, including asthma, allergic rhinitis, conjunctivitis and dermatitis. The purpose of the current study...

Lead sponsor: Circassia Limited•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Circassia Limited

Collaborators

Syneos Health
CIDAL

Age

12 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•History of moderate to severe rhinoconjunctivitis consistent with allergy to grass for at least 2 years.
•Forced Expiratory Volume in 1 Second (FEV1) of at least 70% of predicted value or personal best if available at the Screening Visit.
•Perennial Rye grass or Timothy grass-specific IgE ≥ 0.35 kU/L as measured by ImmunoCAP®.
•Positive skin prick test to Perennial Rye grass or Timothy grass allergen

Exclusion Criteria

•Positive skin prick test ≥ 5 mm to any confounding, co-existing seasonal allergens likely to be present during the pre-season baseline and grass pollen period.
•Medical records of symptomatic perennial allergic rhinitis and/or asthma or a positive skin test ≥ 5 mm due to a perennial allergen to which the subject is regularly exposed (moulds, dust mites, cockroaches, and animal dander) and which cannot be avoided during the course of the study.
•Previous immunotherapy treatment with any grass allergen for more than 1 month within 5 years prior to screening.
•Subjects who had been treated with any non-grass licensed allergen immunotherapy extracts or non-grass investigational immunotherapy for more than 1 month within 1 year.

Related studies

RECRUITINGPhase 3

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990 · Rhinitis, Allergic, Rhinoconjunctivitis, and more

RECRUITINGPhase 4

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT06778213 · Allergic Rhinoconjunctivitis

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

NCT07427576 · Mite Allergy, Dermatophagoides Farinae Allergy, and more

COMPLETEDPhase 2

Study of BLU-808 in Allergic Rhinoconjunctivitis

NCT06922448 · Allergic Rhinoconjunctivitis

COMPLETEDPhase 2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966 · Allergic Rhinoconjunctivitis, Grass Pollen Allergy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 8, 2015Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment109

Start dateApr 2014

Last updatedApr 8, 2015

Condition

Grass Allergy Rhinoconjunctivitis

Locations shown

Washington D.C., District of Columbia

Normal, Illinois

Sylvania, Ohio

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2015Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions